TY  - JOUR
T1  - SERUM ASPROSİN DÜZEYLERİ İLE NONPROLİFERATİF VE PROLİFERATİF DİYABETİK RETİNOPATİ ARASINDA BİR İLİŞKİ VAR MIDIR?
TT  - IS THERE ANY RELATIONSHIP BETWEEN SERUM ASPROSIN LEVELS AND NONPROLIFERATIVE AND PROLIFERATIVE DIABETIC RETINOPATHY?
AU  - Tüfek, Melek
AU  - Aydın, Nihat
AU  - Çapraz, Mustafa
AU  - Tozcu Yılmaz, Duygu
AU  - Gül, Mehmet Ali
PY  - 2025
DA  - October
Y2  - 2025
DO  - 10.53446/actamednicomedia.1679589
JF  - Acta Medica Nicomedia
JO  - Acta Med Nicomedia
PB  - Kocaeli Üniversitesi
WT  - DergiPark
SN  - 2717-8994
SP  - 295
EP  - 300
VL  - 8
IS  - 3
LA  - tr
AB  - Amaç: Çalışmamızdaki amacımız serum asprosin seviyelerinin diyabetik retinopati (DR) patogenezindeki rolünü araştırmak ve diyabetin farklı evreleri için olası farklılıkları ortaya koymaktı.Yöntem: Bu prospektif çalışmaya Tip 2 diyabetes mellitus (T2DM)’lu, 32 nonproliferatif diyabetik retinopati (NPDR), 28 proliferatif diyabetik retinopati (PDR) hastası ile 30 sağlıklı birey dahil edildi. Tüm katılımcıların antropometrik ölçümleri yapıldı. Biyokimyasal parametreler değerlendirildi. Serum asprosin seviyeleri enzyme-linked immunosorbent assay (ELISA) yöntemi kullanılarak analiz edildi.Bulgular: Açlık kan glukozu (AKG), insülin, insülin direncinin homeostaz modeliyle değerlendirmesi (HOMA-IR), hemoglobin A1c (HbA1c), trigliserid ve vücut kitle indeksi (VKİ) değerleri; DR gruplarında kontrol grubuna göre istatistiksel açıdan anlamlı derecede daha yüksek bulundu (p
KW  - Adipokin
KW  - asprosin
KW  - diyabetes mellitus
KW  - diyabetik retinopati
N2  - Objective: Asprosin is a novel adipokine that is released in response to fasting. The aim of this study was to investigate the role of serum asprosin levels in the pathogenesis of diabetic retinopathy (DRP), and to reveal the possible differences for different stages of diabetes. Methods: This prospective study included 32 nonproliferative diabetic retinopathy (NPDRP) and 28 proliferative diabetic retinopathy (PDRP) patients with Type 2 diabetes mellitus (T2DM), and 30 healthy individuals. Anthropometric measurements were performed for all the subjects. Biochemical parameters were evaluated. Serum asprosin levels were analyzed by using the enzyme-linked immunosorbent assay (ELISA) method.Results: The fasting blood glucose (FBG), insulin, homeostasis model assessment of insulin resistance (HOMA-IR), hemoglobin A1c (HbA1c), triglyceride, and body mass index (BMI) values in the DRP groups were found to be statistically significantly higher than in the control group (p
CR  - Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22(8):1566-1569.
CR  - Tan TE, Wong TY. Diabetic retinopathy: Looking forward to 2030. Front Endocrinol (Lausanne). 2023;13:1077669. doi:10.3389/fendo.2022.1077669
CR  - Park YG, Roh YJ. New diagnostic and therapeutic approaches for preventing the progression of diabetic retinopathy. J Diabetes Res. 2016;2016:1753584. doi:10.1155/2016/1753584
CR  - Yang J, Liu Z. Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne). 2022;13:816400. doi:10.3389/fendo.2022.816400
CR  - Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev. 2009;5(1):3-7. doi:10.2174/157339909787314176
CR  - Ghamdi AHA. Clinical predictors of diabetic retinopathy progression; a systemic review. Curr Diabetes Rev. 2020;16(3):242-247. doi:10.2174/1573399815666190215120435
CR  - Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322-1325. doi:10.1111/jdi.13480
CR  - Navaei S, Nazemi S, Emamian MH, Hashemi H, Fotouhi A. Vitamin D deficiency and diabetic retinopathy risk. J Fr Ophthalmol. 2023;46(7):737-741. doi:10.1016/j.jfo.2023.01.024
CR  - Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165(3):566-579. doi:10.1016/j.cell.2016.02.063
CR  - Naiemian S, Naeemipour M, Zarei M, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:65. doi:10.1186/s13098-020-00564-w
CR  - Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A novel player in metabolic diseases. Front Endocrinol (Lausanne). 2020;11:64. doi:10.3389/fendo.2020.00064
CR  - Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583. doi:10.1155/2018/9471583
CR  - American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(suppl 1):14-80. doi:10.2337/dc14-S014
CR  - Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682. doi:10.1016/S0161-6420(03)00475-5
CR  - Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes care. 2004;27(6):1487-1495. doi:10.2337/diacare.27.6.1487
CR  - Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96-104. doi:10.1016/j.mce.2019.03.001
CR  - Papachristoforou E, Lambadiari V, Maratou E, Makrilakis K. Association of gylcemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res. 2020;2020:7489795. doi:10.1155/2020/7489795
CR  - Atlı H, Onalan E, Yakar B, et al. The relationship of serum asprosin level with diabetic and non-diabetic retinopathy. Eur Rev Med Pharmacol Sci. 2022;26(6):2117-2123. doi:10.26355/eurrev_202203_28359
CR  - Oruc Y, Celik F, Ozgur G, et al. Altered blood and aqueous humor levels of asprosin, 4-hydroxynonenal, and 8-hydroxy-deoxyguanosine in patients with diabetes mellitus and cataract with and without diabetic retinopathy. Retina. 2020;40(12):2410-2416. doi:10.1097/IAE.0000000000002776
CR  - Yardim M, Celik F, Oruc Y, et al. Serum asprosin levels in patients with retinopathy of prematurity. Turk J Biochem. 2022;47(6):749-755. doi:10.1515/tjb-2022-0019
CR  - Whitehead M, Wickremasinghe S, Osborne A,Wijngaarden PV, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257-1270. doi:10.1080/14712598.2018.1545836
CR  - Youngblood H, Robinson R, Sharma A, Sharma S. Proteomic biomarkers of retinal inflammation in diabetic retinopathy. Int J Mol Sci. 2019;20(19):4755. doi:10.3390/ijms20194755
CR  - Dai C, Xiao J, Wang C, Li W, Su G. Neurovascular abnormalities in retinopathy of prematurity and emerging therapies. J Mol Med (Berl). 2022;100(6):817-828. doi:10.1007/s00109-022-02195-2
CR  - Goumans MJ, Liu Z, ten Dijke P. TGF-β signaling in vascular biology and dysfunction. Cell Res. 2009;19(1):116-127. doi:10.1038/cr.2008.326
CR  - Muthu ML, Reinhardt DP. Fibrillin -1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. J Cell Commun Signal. 2020;14(2):159-173. doi:10.1007/s12079-020-00566-3
CR  - Shabir K, Gharanei S, Orton S, et al. Asprosin exerts pro-inflammatory effects in THP-1 macrophages mediated via the Toll-like receptor 4 (TLR4) Pathway. Int J Mol Sci. 2022;24(1):227. doi:10.3390/ijms24010227
CR  - Lu Y, Yuan W, Xiong X, et al. Asprosin aggravates vascular endothelial dysfunction via disturbing mitochondrial dynamics in obesity models. Obesity (Silver Spring). 2023;31(3):732-743. doi:10.1002/oby.23656
CR  - Mirr M, Braszak-Cymerman A, Ludziejewska A, et al. Serum asprosin correlates with indirect insulin resistance indices. Biomedicines. 2023;11(6):1568. doi:10.3390/biomedicines11061568
CR  - Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183-188. doi:10.1016/j.cca.2017.10.034
CR  - Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. Invest Ophthalmol Vis Sci. 2011;52(7):4416-4421. doi:10.1167/iovs.11-7208
CR  - Farrag M, Eldjoudi DA, González-Rodríguez M, et al. Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol (Lausanne). 2023;13:1101091. doi:10.3389/fendo.2022.1101091
CR  - Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.
CR  - Hietala K, Wadén J, Forsblom C, et al. FinnDiane Study Group. HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia. 2013;56(4):737-745. doi:10.1007/s00125-012-2816-6
CR  - Matsushita Y, Yokoyama T, Takeda N, et al. A comparison in the ability to detect diabetic retinopathy between fasting plasma glucose and HbA1c levels in a longitudinal study. Endocrinol Diabetes Metab. 2020;4(1):e00196. doi:10.1002/edm2.196
CR  - Li J, Shi L, Zhao G, et al. High triglyceride levels increase the risk of diabetic microvascular complications: a cross-sectional-study. Lipids Health Dis. 2023;22(1):109. doi:10.1186/s12944-023-01873-5
CR  - Duţă I, Fica S, Ion DA. The association between insulin resistance and proliferative retinopathy in Type 1 diabetes. Rom J Intern Med. 2015;53(3):261-266. doi:10.1515/rjim-2015-0034
UR  - https://doi.org/10.53446/actamednicomedia.1679589
L1  - https://dergipark.org.tr/tr/download/article-file/4788250
ER  -